Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients

December 9, 2010
PDF Version
Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients Phase 2 data to be presented at 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology